HEMISPHERX BIOPHARMA INC (HEB) Forecast, Price Target & Analyst Ratings

NYSEARCA:HEB

Current stock price

1.8
-0.01 (-0.55%)
At close:
1.77
-0.03 (-1.67%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for HEMISPHERX BIOPHARMA INC (HEB).

Forecast Snapshot

Consensus Price Target

Price Target
N/A
N/A

Next Earnings Forecast

Earnings Estimate
Release Date
N/A

ChartMill Buy Consensus

Rating
60.00%
Weighted Analyst Rating Score

Price Target Details & History

Consensus Price Target and Range

Mean target
N/A
Upside
N/A
From current price of $1.80 to mean target of N/A, Based on 1 analyst forecasts
Low
N/A
Median
N/A
High
N/A

Price Target Revisions

1 Month
N/A
3 Months
N/A

Price Target Summary

Analyst Ratings & History

Current Analyst Ratings

HEB Current Analyst RatingHEB Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.2 0.4 0.6 0.8

Analyst Ratings History

HEB Historical Analyst RatingsHEB Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -8 -7 -6 -5 -4 -3 -2 -1 0 0.2 0.4 0.6 0.8

Analyst Ratings Consensus

ChartMill Buy Consensus
60.00%
HEB was analyzed by 1 analysts. The buy percentage consensus is at 60. So analysts seem to be rather neutral about HEB.
In the last month the buy percentage fell by 40 points. So the trust of analysts is decreasing.
Only 1 analysts analyzed HEB. So this is just the average opinion of a couple of analysts.

Recent Upgrades & Downgrades

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
N/A
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A

HEMISPHERX BIOPHARMA INC / HEB Forecast FAQ